Search | metanaruay

2026-01-06 09:57:42

Evaluating the 2026 Growth of Biosimilars and Specialty Generics within the Oncology and Autoimmune Therapeutic Areas of the Germany Generic Pharmaceuticals Sector

In early 2026, the most lucrative segment of the German off-patent industry is shifting toward "complex generics" and biosimilars as several high-value biologic patents expire across the European Union. These 2026 biosimilar launches are drastically reducing the cost of treatment for oncology and rheumatoid arthritis, allowing statutory health insurers to redirect savings toward other...

0 ความคิดเห็น 0 แชร์ 171 ยอดวิว 0 รีวิว